Home » Posts tagged with » Gilead Sciences
Gilead to acquire stake in cancer immunotherapy company Pionyr Immunotherapeutics

Gilead to acquire stake in cancer immunotherapy company Pionyr Immunotherapeutics

Gilead Sciences has agreed to acquire a stake of 49.9% in California-based cancer immunotherapy company Pionyr Immunotherapeutics, for $275 million. The pharma major has also secured an exclusive option to acquire the remaining stake in Pionyr Immunotherapeutics. As per the agreement, shareholders of the cancer immunotherapy company could be paid an additional $1.47 billion in […]

Gilead Covid-19 drug candidate remdesivir delivers desired results in phase 3 trial

Remdesivir clinical trial results : Gilead Sciences said that the phase 3 SIMPLE trial, which has been evaluating the Covid-19 drug candidate remdesivir for the treatment of hospitalized patients with moderate pneumonia associated with novel coronavirus, has yielded promising results. According to the US biopharma company, the Covid-19 drug candidate delivered significantly greater clinical improvement for […]

Continue reading …
FDA grants EUA for Gilead’s investigational COVID-19 drug remdesivir

Remdesivir EUA status : The US has officially pushed the use of remdesivir for treating the novel coronavirus with the Food and Drug Administration (FDA) granting emergency use authorization (EUA) to the investigational COVID-19 drug candidate being developed by Gilead Sciences. The EUA lets the antiviral drug candidate to be used for the treatment of […]

Continue reading …
Gilead Sciences wraps up $4.9bn acquisition of Forty Seven

Gilead Sciences has completed its previously announced $4.9 billion acquisition of Forty Seven, a clinical-stage immuno-oncology company based in California. The immuno-oncology company has been acquired by the US biotech company for $95.50 per share in cash to become the latter’s fully-owned subsidiary. Forty Seven will be delisted from the Nasdaq Global Select Market. The […]

Continue reading …
Gilead Sciences, Second Genome form IBD drug discovery alliance

Gilead Sciences has entered into a four-year deal worth up to $338 million with California-based clinical-stage company Second Genome to discover targets and drug candidates for the treatment of inflammatory bowel disease (IBD). The companies will also collaborate on detecting biomarkers related to clinical response for a maximum of five pipeline compounds of Gilead Sciences, […]

Continue reading …
Gilead Sciences bags Epclusa FDA approval for hepatitis C in pediatric patients

Epclusa FDA approval : Gilead Sciences has secured an expanded approval for Epclusa (sofosbuvir 400mg/velpatasvir 100mg; sofosbuvir 200mg/velpatasvir 50 mg) from the US Food and Drug Administration (FDA), which covers treatment of chronic hepatitis C infection (HCV) in children. The approval is for the drug to be used for the treatment of children aged six […]

Continue reading …
Gilead Sciences to acquire immuno-oncology company Forty Seven for $4.9bn

Gilead Sciences acquisition of Forty Seven : US biotech company Gilead Sciences has signed an all-cash deal worth around $4.9 billion to acquire Forty Seven, a clinical-stage immuno-oncology company based in California, as per the latest pharma acquisition news. The immuno-oncology company is being acquired by Gilead Sciences for $95.50 per share in cash. Through […]

Continue reading …
Gilead Sciences bags Descovy FDA approval for prevention of HIV infection

Descovy FDA approval : Gilead Sciences’ Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets; F/TAF) has been approved by the US Food and Drug Administration for HIV Pre-Exposure Prophylaxis (PrEP) or in other words prevention of HIV infection.. PrEP is defined as an HIV prevention method in which medicine is taken everyday before […]

Continue reading …
Gilead Sciences announces Biktarvy China approval for HIV-1

Biktarvy China approval : US biopharma company Gilead Sciences said that the China National Medical Products Administration (NMPA) has approved Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF) for the treatment of HIV-1 infection. The once-daily single tablet regimen (STR) Biktarvy is a combination of the unboosted integrase strand transfer inhibitor (INSTI) bictegravir and the dual […]

Continue reading …
Gilead Sciences licenses three preclinical antiviral programs from Novartis

US biopharma company Gilead Sciences has licensed three preclinical antiviral programs, including investigational candidates having the potential to treat human rhinovirus, influenza and herpes viruses, from Swiss pharma company Novartis. As per the agreement, Gilead Sciences will get exclusive global rights for the development and commercialization of small molecules against three undisclosed targets. Novartis will […]

Continue reading …
Page 1 of 212